A new Collaborative Research Centre (CRC) at the University of Cologne will receive funding from the DFG for the next three years and nine months to investigate age-related eye diseases that lead to blindness. Two other existing CRCs from the fields of cell death research and climate change in the Arctic are entering the next funding period: They will receive further millions of funding to continue their work.
“I would like to congratulate all the scientists involved on this success. We are pleased that all three of the projects applied for are being funded. The funding approval shows that the University of Cologne is an outstanding location for forward-looking and socially highly relevant research,” said Professor Dr Joybrato Mukherjee, Rector of the University of Cologne.
Fight against blindness
The new CRC 1607 ‘Immunomodulating and anti(lymph)angiogenic therapies for age-related eye diseases that can lead to blindness’ investigates how eye diseases that occur in old age and develops novel treatments for these diseases. The spokesperson is Professor Dr Claus Cursiefen, Chairman of the Department of Ophthalmology at the University Hospital Cologne and associated priniple investigators at the CECAD - the University of Cologne’s Cluster of Excellence for Aging Research.
The causes of several blinding eye diseases are poorly understood and there are no good treatments. Many of these diseases are age-dependent, so they are likely to be more common in an ageing society. Apart from the loss of quality of life and independence for individuals, these diseases will therefore burden society as a whole.
Previous research – also in the DFG Research Unit 2240 at the Department of Ophthalmology at University of Cologne – indicates that defective cellular immune responses (inflammation) and/or pathological growth of blood and lymph vessels in later life lead to a large number of age-associated eye diseases. These include ‘common diseases’ such as age-related macular degeneration, dry eye syndrome and glaucoma or corneal dystrophy. A large proportion of the population suffers from these and other age-related eye diseases. More than half of those over sixty are affected.
The scientists at the new Collaborative Research Centre want to make significant progress in understanding the diseases and in clinical translation – in other words, the transition from basic research to clinical application. “CRC 1607 has a unique and important position, as there is currently no other international research centre that focuses on the role of lymph and blood vessels and immune cells in age-associated eye diseases,” said Professor Dr Cursiefen. “We are therefore very pleased that the DFG's funding commitment enables us to close this gap. Since this is only the second CRC in the field of ophthalmology in the history of the DFG, this is also a huge benefit for our field and our patients.” The aim of the researchers is to decipher the disease mechanisms of age-associated eye diseases with particular attention to the role of cellular immunity and inflammation as well as the growth of blood and lymph vessels. Innovative new treatment concepts are to be developed which are built on this.
The new CRC will receive funding of around 13 million euros from the DFG for the first funding phase until the end of 2027.
Keeping tissues healthy
CRC 1403 ‘Cell death in immunity, inflammation and diseases‘, which was established at the University of Cologne in 2020, will receive a total of around 12.6 million euros for a further four years.
The scientists of the Collaborative Research Centre 1403 are pursuing a multidisciplinary approach to provide answers to new questions in cell death research. Cell death is a fundamental biological process in multicellular organisms that is crucial to maintaining tissue functions, for example when they come into contact with and fight off pathogens. Recent research has shown that cells can choose between different types of regulated cell death, which have different effects on the surrounding tissue and trigger corresponding reactions in its cells. The aim of CRC 1403 is to understand the regulatory mechanisms as well as the physiological and pathological consequences of different types of cell death in the organism.
The speakers are Professor Dr Manolis Pasparakis from the Institute for Genetics and Professor Dr Hamid Kashkar (deputy spokesperson) from the Institute for Molecular Immunology (both of the University of Cologne). Not only genetics but also botany, dermatology, internal medicine and molecular immunology are involved in the 21 sub-projects. CRC 1403 is a cooperation between the University of Cologne and the Max Planck Institute for Plant Breeding Research, the Max Planck Institute for Biology of Ageing, as well as partners at the University of Bonn, the LMU Munich, the University of Freiburg and the German Rheumatism Research Centre Berlin (DRFZ). “We are very pleased that we can continue our interdisciplinary collaboration on the subject of cell death, immunity, inflammation and diseases. This additional funding will allow us to gain important insights into the mechanisms of cell death and immunity and to use them for a better understanding of the pathophysiology of inflammatory diseases,” said Professor Dr Manolis Pasparakis, who is priniple investigators at the Aging Research Excellence Cluster CECAD too.
Understanding Arctic climate change
The aim of CRC/TR 172 ‘Arctic Amplification (AC)³’, which has been funded since 2016 and has now been extended, is to monitor and understand the dramatic climate development in the Arctic using various methods to improve the reliability of models for predicting observed on-site warming. The above-average warming – known as Arctic amplification – is due to a variety of factors that affect the climate in the Arctic, but are not yet fully known.
In the first phase, the participating researchers carried out three complex cloud measurement operations in the Arctic. In the second phase, the investigations were extended to the inner Arctic and to a whole year as an observation period in order to quantify seasonal differences. At the same time a unique modelling chain has been developed. In the following third funding period, the focus will be on bringing together the various observations and modelling approaches to form an overall understanding for better predictions. A special focus is on how clouds develop during the transport of air masses into and out of the Arctic. In addition to analyses of the MOSAiC campaign, the long-term measurements in Ny-Ålesund and modelling on the hectometer scale, special measurements will be carried out with the new Cologne-based GRAWAC large-scale instruments from the Polar 5 aircraft over sea ice.
The approved sum for the new funding period amounts to almost 4 million euros. Co-applicant Professor Dr Susanne Crewell from the University of Cologne says: “In recent years, we have gained a large number of new measurements in the Arctic that show the strong dynamics of the climate system there. Over the next four years, we now want to use these to improve numerical models in order to better predict the future development of the Arctic in a warmer climate.”
SFB 1607: Professor Dr Claus Cursiefen
Centre for Ophthalmology / University Hospital Cologne
+49 221 478-5094
SFB 1403: Professor Dr Manolis Pasparakis
Institute for Genetics
CECAD – Cluster of Excellence I Cellular Stress Responses in Ageing-Associated Diseases
+49 221 478-84351
SFB/TRR 172: Professor Dr Susanne Crewell
Institute of Geophysics and Meteorology
+49 221 470-5286
Press and Communications Team:
+49 221 470 2356
CECAD Public Relations Officer
+49 221 478 84043
+49 160 8879816
Press Spokesperson: Dr Elisabeth Hoffmann – firstname.lastname@example.org